DIANTHUS THERAPEUTICS INC (DNTH)
Health Care · biotechnology · NASDAQ
Dianthus Therapeutics is a clinical-stage biotechnology firm developing antibody-based complement inhibitors to treat severe autoimmune disorders.
What DIANTHUS THERAPEUTICS INC does
Dianthus Therapeutics is a clinical-stage biotechnology company focused on the development of novel antibody-based therapies for severe autoimmune diseases. Its lead product candidate, claseprubart, is designed to target the complement system, while its pipeline also includes DNTH212. The company is currently engaged in research and development activities and clinical trials.
Themes: autoimmune diseases, complement therapeutics, drug development
Fundamentals
- Price$82.43 as of 2026-10-08 close
- Market cap$4.6B as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return+137.2% 2025-10-08 close $34.75 → 2026-10-08 close $82.43
- P/En/a negative earnings
- Net margin-7973.3% FY2025, SEC XBRL
- ROE-32.9% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)-60.8% as of 2026-09-03
- Beta1.09 as of 2026-09-03
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How DNTH compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DNTH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
33.2 #1315 of 1,379 scored · #142 of 151 in Health Care
Financial health 94th (debt to equity 0) and trend 55th (over the past 12 months this stock beat the market by 122.2 percentage points); weakest is growth (1st, revenue growth year over year -60.8%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How DIANTHUS THERAPEUTICS INC looks technically
DIANTHUS THERAPEUTICS INC (DNTH) is trading 1.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 270 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 23, in oversold territory (below 30). It just made a new 20-day low, its first since 2026-06-17, breaking below its recent trading range. It is 30.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 1.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $103.23 | $103.23 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $80.96 | $80.96 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 111.11. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 270 trading days ago — a "golden cross", a bullish long-term signal | 270 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control | 39.0 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 23, in oversold territory (below 30) | 23.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($81.10 to $100.47) — its "stochastic" reading is 7 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 6.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 35 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $117.88 | $117.88 |
|---|---|---|
| From the 52-week high | it is 30.1% below its 52-week high (its highest price of the past year) | -30.1% |
| Above the 52-week low | it is 155.8% above its 52-week low (its lowest price of the past year) | +155.8% |
| Below the 52-week high | it is 30.1% below its highest point of the past year | 30.1% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-06-17, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-06-17, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $336.00 (set on 2019-03-26) | $336.00 |
| Given back of the 52-week move | over the past year its closes ranged ($32.92 to $115.96), and it has given back roughly a third of its rise from last year’s low — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $61.98 to $64.64. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 40.4% |
| From the all-time high | it is 75.5% below its all-time high | -75.5% |
| Nearest price level | it is trading 6.4% below a resistance level at $87.71 — a price it turned at twice since 2026-03-11, most recently on 2026-07-02. Since 2024-10-08 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.4% |
| All-time low | its lowest closing price on record is $5.12 (set on 2022-12-21) | $5.12 |
| Above the all-time low | it is 1510.0% above its all-time low | +1,510% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $4.45 between its high and its low — about 5.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $4.45 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $78.16 and $108.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $78.16 – $93.35 – $108.53 |
| Typical daily range (% of price) | its price moves about 5.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.4% |
| Stretch from the 200-day average | it is trading 0.3 daily ranges above its 200-day average price (1.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.24× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a hammer | 7 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.2% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 5 sessions in a row, a -6.67% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 5 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 25.5 percentage points (the stock lost 24.5% while the market gained 1.0%) | -25.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 19.8 percentage points (the stock lost 15.9% while the market gained 3.8%) | -19.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 21.0 percentage points (the stock lost 3.6% while the market gained 17.5%) | -21.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 122.2 percentage points (the stock gained 137.2% while the market gained 15.0%) | +122.2% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -16.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $83.35 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -1.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 19% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $101.41 — a volume-weighted average of daily closes over 47 sessions, not a true tick-by-tick VWAP. | -18.7% |
Price levels it has turned at before
DNTH last closed at $82.43 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $87.71 | Resistance | 6.4% above the last close | turned there twice · 2026-03-11 to 2026-07-02 |
| $74.97 | Support | 9.1% below the last close | turned there twice · 2026-03-23 to 2026-06-11 |
| $91.41 | Resistance | 10.9% above the last close | turned there twice · 2026-05-06 to 2026-07-17 |
| $99.35 | Resistance | 20.5% above the last close | turned there twice · 2026-06-30 to 2026-07-28 |
| $45.55 | Support | 44.7% below the last close | turned there twice · 2025-12-04 to 2026-02-12 |
| $40.06 | Support | 51.4% below the last close | turned there three times · 2025-09-18 to 2025-12-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $111.11.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 18 trading days, since 2026-09-15.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.06 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$140.80 range $122.00 – $200.00; median $134.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DNTH
- Consensus EPS estimate-$0.9486 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.07135 from -$1.02, on 2026-09-03, 35-day window
- Readings revised upward33% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependence on the clinical success and regulatory approval of its lead product candidates, claseprubart and DNTH212.","Significant risks related to the company's ability to manage its cash resources and secure additional funding given its current unprofitable, R&D-heavy business model.","Uncertainty in clinical trial outcomes and the potential failure to replicate positive preclinical data in human subjects."]
What changed in the latest 10-Q
AI-assisted comparison of DNTH's 10-Q filed 2026-08-04 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-04) adds a paragraph introducing DNTH312 as an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target inhibition of active C1s and BAFF/APRIL, enhanced with YTE half-life extension technology, designed to expand leadership in autoimmune diseases.
- Newer filing (2026-08-04) states that in June 2026 the company announced the initiation of the Phase 3 registrational EMERGE trial of claseprubart in gMG.
- Newer filing (2026-08-04) adds details on the Phase 3 CAPTIVATE trial interim responder analysis, stating a 75% response rate was observed in June 2026 from the first 40 participants completing Part A, exceeding the target response rate of 50% or greater, with results consistent and clinically meaningful across multiple efficacy measures, and that claseprubart was generally well tolerated with no related serious infections, no clinical symptoms of DIL, no related SAEs or discontinuations due to safety.
- Newer filing (2026-08-04) states that in August 2026 the company announced completion of enrollment of the Phase 2 MoMeNtum trial for MMN, which exceeded its enrollment target of 36 patients, and top-line results with 46 patients are expected in December 2026.
- Removed:
- Older filing (2026-05-05) states the company expected to initiate a Phase 3 registrational trial in gMG in mid-2026 and report top-line results in the second half of 2028.
- Older filing (2026-05-05) states the company anticipated initial top-line results from the Phase 2 MoMeNtum trial for MMN would be available in the fourth quarter of 2026.
- Older filing (2026-05-05) contains detailed discussion of the Phase 2 MaGic trial positive top-line data, including specific efficacy endpoints (MG-ADL, QMG, MSE, MGC, MG-QoL-15r), safety observations (no drug-related SAEs, no treatment-related serious bacterial infections, no clinical symptoms of emergent autoimmune disorders), and OLE data supporting potential 300mg Q4W dosing.
- Older filing (2026-05-05) describes the Phase 2 MaGic trial open-label extension data in detail, including robust reductions in MG-ADL and QMG after two doses of 600mg Q2W at PK levels far below steady state.
- Reworded:
- Newer filing (2026-08-04) changes 'three mid- to late-stage clinical trials' to 'mid- to late-stage clinical trials' (removing the explicit count of three).
- Newer filing (2026-08-04) changes 'screening criteria' to 'screening criterion' in the FDA feedback bullet regarding removal of ANAs.
- Newer filing (2026-08-04) changes 'drug-induced lupus (“DIL”)' to 'Systemic Lupus Erythematosus to DIL' in the third FDA feedback bullet, altering the wording referencing the reclassification from the hypothetical risk of SLE to DIL.
- Newer filing (2026-08-04) changes 'interim responder analysis' to 'Interim Responder Analysis' in the CAPTIVATE trial description (capitalization change).
- Newer filing (2026-08-04) updates the CAPTIVATE trial description from an early GO announcement (without interim responder analysis response rate details) to include the 75% response rate and comparative details announced in June 2026.
- Newer filing (2026-08-04) updates the MoMeNtum trial description from anticipated initial top-line results in Q4 2026 to completion of enrollment in August 2026 exceeding the 36-patient target and top-line results with 46 patients expected in December 2026.
- Newer filing (2026-08-04) updates the gMG program description from expected Phase 3 trial initiation in mid-2026 to announced initiation of the Phase 3 EMERGE trial in June 2026 with top-line results expected in the second half of 2028.
- Notes:
- The newer MD&A text is truncated mid-sentence at 'Myasthenia Gravis Qu' while the older text is truncated at 'Based on the outcome of our end-of-Phase 2 meetin', limiting comparison of content beyond those truncation points.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 30 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 5 sells ($2M) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 30 sells ($26M) — 6 selling insiders
- Last 180 days · read to 2026-10-040 buys · 39 sells ($34M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-17. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DNTH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding DNTH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 16,732,977
- Reported value $1,631,125,981
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DNTH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DNTH had 8,829,663 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
DNTH had 15.8% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.42 days to cover at the same settlement.
- Reported short interest (shares) 8,829,663
- Short interest (% of shares outstanding) 15.8%
- Prior settlement (shares) 8,429,902
- Reported change 4.74%
- Days to cover (reported) 14.42
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
DIANTHUS THERAPEUTICS INC is found in…
Frequently asked questions
What does DIANTHUS THERAPEUTICS INC (DNTH) do?
Dianthus Therapeutics is a clinical-stage biotechnology company focused on the development of novel antibody-based therapies for severe autoimmune diseases. Its lead product candidate, claseprubart, is designed to target the complement system, while its pipeline also includes DNTH212. The company is currently engaged in research and development activities and clinical trials.
What sector is DIANTHUS THERAPEUTICS INC (DNTH) in?
DIANTHUS THERAPEUTICS INC (DNTH) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Is DIANTHUS THERAPEUTICS INC (DNTH) overbought or oversold right now?
DIANTHUS THERAPEUTICS INC (DNTH) is currently in oversold territory (its 14-day RSI is 23, below 30) (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DNTH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.